论文部分内容阅读
目的:分析更昔洛韦治疗小儿手足口病的临床效果。方法:纳入该院住院部在时间段2015年8月至2016年1月区间手足口病患儿共60例作为观察对象,按照入院编号奇偶性方法进行分组,分别将30例患者纳入对照组、观察组中。对照组确诊后用药利巴韦林,观察组确诊后用药更昔洛韦。以临床有效性以及用药期间安全性为评价指标,对比两组患儿经不同方法干预后治疗效果的差异。结果:观察组经治疗后临床总有效率为90.00%,显著高于对照组(66.67%,P<0.05)。观察组用药期间并发症总发生率为3.33%(1/30),显著低于对照组(20.00%,P<0.05)。结论:更昔洛韦治疗小儿手足口病的综合价值突出,有效性高且用药安全可靠,值得进一步推广应用。
Objective: To analyze the clinical effect of ganciclovir in the treatment of hand-foot-mouth disease in children. Methods: Sixty children with hand-foot-mouth disease admitted to the inpatient department of the hospital during the period from August 2015 to January 2016 were selected as observation objects and grouped according to the parity number of hospital admission. Thirty patients were included in the control group, Observation group. The control group was treated with ribavirin, and the observation group was treated with ganciclovir. The clinical effectiveness and safety during the treatment period were used as the evaluation indexes to compare the difference of treatment effect between two groups of children after intervention by different methods. Results: The total clinical effective rate in the observation group after treatment was 90.00%, significantly higher than that in the control group (66.67%, P <0.05). The total incidence of complications during the observation group was 3.33% (1/30), significantly lower than the control group (20.00%, P <0.05). Conclusion: The comprehensive value of ganciclovir for the treatment of HFMD in children is outstanding, its efficacy is high, and the medication is safe and reliable, which deserves further application.